Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.85 USD
Change Today +0.32 / 3.75%
Volume 1.2M
TROV On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

trovagene inc (TROV) Snapshot

Open
$8.90
Previous Close
$8.53
Day High
$9.02
Day Low
$8.50
52 Week High
04/17/15 - $9.18
52 Week Low
08/1/14 - $2.97
Market Cap
215.7M
Average Volume 10 Days
541.1K
EPS TTM
$-0.85
Shares Outstanding
24.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TROVAGENE INC (TROV)

trovagene inc (TROV) Related Bloomberg News

View More Bloomberg News

trovagene inc (TROV) Related Businessweek News

No Related Businessweek News Found

trovagene inc (TROV) Details

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It is developing PCM BRAF and KRAS mutation detection tests for detecting mutations in metastatic cancer patients; and HPV HR detection test to detect the presence of various HPV genotypes using a urine sample. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

31 Employees
Last Reported Date: 03/12/15
Founded in 1999

trovagene inc (TROV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $539.0K
Chief Financial Officer
Total Annual Compensation: $338.8K
Chief Scientific Officer
Total Annual Compensation: $430.0K
Compensation as of Fiscal Year 2014.

trovagene inc (TROV) Key Developments

Trovagene, Inc. Appoints Matthew L. Posard as Executive Vice President & Chief Commercial Officer

Trovagene, Inc. announced that Matthew L. Posard has joined the company as executive vice president & chief commercial officer. Most recently, he led the new and emerging market opportunities business at Illumina, Inc.

TrovaGene, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

TrovaGene, Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of $56,000 against $47,000 a year ago. Loss from operations was $4,504,000 against $2,849,000 a year ago. Net loss available to common shareholders was $4,689,000 or $0.25 per basic and diluted share against $1,038,000 or $0.05 per basic share a year ago. The change in net loss is primarily due to an increase in total operating expenses of $1.7 million and a change in the fair value of derivative instruments related to warrants of $1.6 million, as compared to the prior year period. For the year, the company reported revenue of $280,000 against $259,000 a year ago. Loss from operations was $14,945,000 against $10,691,000 a year ago. Net loss available to common shareholders was $14,348,000 or $0.88 per diluted share against $11,841,000 or $0.70 per basic share a year ago. The change in net loss is due primarily to an increase in total operating expenses of $4.3 million, offset by a change in the fair value of derivative instruments related to warrants of $2.5 million, as compared to the prior year period.

TrovaGene, Inc. to Report Q4, 2014 Results on Mar 12, 2015

TrovaGene, Inc. announced that they will report Q4, 2014 results at 2:00 PM, Pacific Standard Time on Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TROV:US $8.85 USD +0.32

TROV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $44.47 USD +0.50
Genomic Health Inc $31.13 USD +0.75
Laboratory Corp of America Holdings $125.35 USD +0.94
Veracyte Inc $8.42 USD -0.41
View Industry Companies
 

Industry Analysis

TROV

Industry Average

Valuation TROV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 575.5x
Price/Book 19.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 583.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TROVAGENE INC, please visit www.trovagene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.